Press Release | NeoGenomics Laboratories

December 5, 2022

NeoGenomics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

November 21, 2022

RaDaR(R) Assay Demonstrates Clinical Potential for Detecting Disease Recurrence Across All Types of Early Breast Cancer, Including Triple Negative Disease

November 18, 2022

NeoGenomics and ImmunoGen Launch New Program Giving Ovarian Cancer Patients Access to Novel FR Biomarker Testing to Support the Launch of ELAHERE(TM)

November 8, 2022

NeoGenomics Reports Third Quarter 2022 Results

November 7, 2022

NeoGenomics Appoints David Perez, Industry Veteran and Former Terumo BCT CEO, to Its Board of Directors

October 28, 2022

NeoGenomics Provides Update on MolDX Submission for CRC and RaDaR(TM) Commercial Launch

October 13, 2022

NeoGenomics Schedules its Third Quarter 2022 Earnings Release for November 8, 2022

October 3, 2022

NeoGenomics Lab Operations | Hurricane Ian Update

Contact Us To Get Started!

Work with us – your premier oncology partner – to optimize cancer care for patients